{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:04:30Z","timestamp":1785431070760,"version":"3.56.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/aim<\/jats:title>\n                    <jats:p>Hyperparathyroidism (HPTH) is a common feature in patients with X-linked hypophosphatemia (XLH), especially when treated with vitamin D analogs and phosphate supplements. Although the exact mechanism is not clear, it is assumed that prolonged intake of phosphate supplements stimulates parathyroid hormone (PTH) secretion. We prospectively assessed the effect of burosumab on PTH levels in children with XLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Thirty-seven children (8.8 \u00b1 3.2 years) were switched from phosphate supplements and vitamin D analogs to burosumab and completed at least 3 years of therapy. Biochemical parameters of calcium-phosphate homeostasis were measured at baseline and prospectively every 6 months. Target serum phosphate under burosumab was &amp;gt;1.2\u2005mmol\/L (&amp;gt;3.7\u2005mg\/dL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 3 years of treatment, there was a global increase of PTH levels from 39.1 \u00b1 18.2 to 54.8 \u00b1 27.6\u2005ng\/L (P = .001) (normal range 18.5-88\u2005ng\/L). Four of 37 subjects (10.8%) developed secondary HPTH after 3 years. None developed tertiary HPTH. Subjects who developed HPTH had higher serum phosphate at M36 (1.33 vs 1.19\u2005mmol\/L, P = .11, respectively), in comparison with those without HPTH. A significant increase in PTH was correlated with the increase in serum phosphate &amp;gt;1.3\u2005mmol\/L (P = .012); serum phosphate positively and independently correlated with PTH in logistic regression analysis (odds ratio = 2.1, 95% CI = 1.1-3.8, P = .021).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We suggest that higher serum phosphate levels in the context of prolonged treatment with burosumab may stimulate PTH secretion in some patients with XLH, leading to HPTH. Careful follow-up and preventive measures to limit the development of secondary HPTH should be applied in treated children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag127","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:06:43Z","timestamp":1784722003000},"page":"165-172","source":"Crossref","is-referenced-by-count":0,"title":["Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia"],"prefix":"10.1093","volume":"195","author":[{"given":"Volha V","family":"Zhukouskaya","sequence":"first","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugurtha","family":"Berkenou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology for Children and Adolescent Medicine, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Audrain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology for Children and Adolescent Medicine, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bardet","sequence":"additional","affiliation":[{"name":"Inserm UMR_S1333 Sant\u00e9 Orale, Universit\u00e9 Paris Cit\u00e9 and Sorbonne Paris Nord , Montrouge ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Inserm UMR_S1333 Sant\u00e9 Orale, Universit\u00e9 Paris Cit\u00e9 and Sorbonne Paris Nord , Montrouge ,","place":["France"]},{"name":"Department of Odontology-Rare Disorders, AP-HP Hospital Bretonneau, Universit\u00e9 de Paris, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9246-5160","authenticated-orcid":false,"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Department of Endocrinology and Diabetology for Children and Adolescent Medicine, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenicky","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Department of Endocrinology and Reproductive Diseases, AP-HP Bic\u00eatre Paris-Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Inserm UMR-S 1185, Physiologie et Physiopathologie Endocriniennes, Universit\u00e9 Paris-Saclay , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-002X","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Department of Endocrinology and Diabetology for Children and Adolescent Medicine, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Inserm UMR-S 1185, Physiologie et Physiopathologie Endocriniennes, Universit\u00e9 Paris-Saclay , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-0975","authenticated-orcid":false,"given":"Diana-Alexandra","family":"Ertl","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, DMU SEA, OSCAR fili\u00e8re, EndoRare and BOND ERN, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Department of Endocrinology and Diabetology for Children and Adolescent Medicine, AP-HP Bic\u00eatre Paris Saclay Hospital , Le Kremlin Bic\u00eatre ,","place":["France"]},{"name":"Inserm UMR-S 1185, Physiologie et Physiopathologie Endocriniennes, Universit\u00e9 Paris-Saclay , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"7","key":"2026073012301970700_lvag127-B1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"2026073012301970700_lvag127-B2","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026073012301970700_lvag127-B3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2026073012301970700_lvag127-B4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2026073012301970700_lvag127-B5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026073012301970700_lvag127-B6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"10189","key":"2026073012301970700_lvag127-B7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2026073012301970700_lvag127-B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2026073012301970700_lvag127-B9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026073012301970700_lvag127-B10","doi-asserted-by":"publisher","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"2026073012301970700_lvag127-B11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026073012301970700_lvag127-B12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"issue":"7","key":"2026073012301970700_lvag127-B13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026073012301970700_lvag127-B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"M\u00e4kitie","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026073012301970700_lvag127-B15","doi-asserted-by":"publisher","first-page":"105208","DOI":"10.1016\/j.jbspin.2021.105208","article-title":"X-linked hypophosphatemia and burosumab: practical clinical points from the French experience","volume":"88","author":"Bacchetta","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2026073012301970700_lvag127-B16"},{"issue":"1","key":"2026073012301970700_lvag127-B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00223-017-0333-9","article-title":"Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia","volume":"102","author":"Mace","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"2026073012301970700_lvag127-B18","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1002\/jcp.26525","article-title":"Effects of FGF-23-mediated ERK\/MAPK signaling pathway on parathyroid hormone secretion of parathyroid cells in rats with secondary hyperparathyroidism","volume":"233","author":"Chen","year":"2018","journal-title":"J Cell Physiol"},{"issue":"2","key":"2026073012301970700_lvag127-B19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1210\/endo-111-2-650","article-title":"Secondary hyperparathyroidism in X-linked hypophosphatemic mice","volume":"111","author":"Kiebzak","year":"1982","journal-title":"Endocrinology"},{"issue":"6","key":"2026073012301970700_lvag127-B20","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jcem.78.6.8200940","article-title":"Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia","volume":"78","author":"Carpenter","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026073012301970700_lvag127-B21","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026073012301970700_lvag127-B22","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","article-title":"Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level","volume":"108","author":"Imel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026073012301970700_lvag127-B23","doi-asserted-by":"publisher","first-page":"117324","DOI":"10.1016\/j.bone.2024.117324","article-title":"Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during burosumab treatment","volume":"190","author":"Padidela","year":"2025","journal-title":"Bone"},{"issue":"1","key":"2026073012301970700_lvag127-B24","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag127\/69857972\/lvag127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/1\/165\/69857972\/lvag127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/1\/165\/69857972\/lvag127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:30:22Z","timestamp":1785429022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/1\/165\/8740378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag127","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]}}}